Pharma in China will face reduced investor confidence

Significance Drugmakers in China face various challenges, including a tightened data governance regime, tough licensing and distribution regulations, and arbitrary investigations coinciding with poorer diplomatic relations. Impacts Recent incidents could undermine the potential boost to foreign investor sentiment from healthcare market openings. Foreign pharmaceutical players will become more wary of compliance risks in new medicine development and rollout. The event could also reignite concerns about cross-border data transfers despite some regulatory easing for data exports earlier in 2024. Companies will worry about being targeted by sporadic investigations without warning, increasing their compliance monitoring.